Model-Estimated Association Between Simulated US Elementary School-Related SARS-CoV-2 Transmission, Mitigation Interventions, and Vaccine Coverage Across Local Incidence Levels.
Adolescent
COVID-19
/ epidemiology
COVID-19 Vaccines
Child
Child, Preschool
Communicable Disease Control
/ organization & administration
Female
Humans
Incidence
Male
Models, Statistical
Risk Assessment
SARS-CoV-2
Schools
/ organization & administration
Students
/ statistics & numerical data
Vaccination Coverage
/ statistics & numerical data
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 02 2022
01 02 2022
Historique:
entrez:
14
2
2022
pubmed:
15
2
2022
medline:
24
2
2022
Statut:
epublish
Résumé
With recent surges in COVID-19 incidence and vaccine authorization for children aged 5 to 11 years, elementary schools face decisions about requirements for masking and other mitigation measures. These decisions require explicit determination of community objectives (eg, acceptable risk level for in-school SARS-CoV-2 transmission) and quantitative estimates of the consequences of changing mitigation measures. To estimate the association between adding or removing in-school mitigation measures (eg, masks) and COVID-19 outcomes within an elementary school community at varying student vaccination and local incidence rates. This decision analytic model used an agent-based model to simulate SARS-CoV-2 transmission within a school community, with a simulated population of students, teachers and staff, and their household members (ie, immediate school community). Transmission was evaluated for a range of observed local COVID-19 incidence (0-50 cases per 100 000 residents per day, assuming 33% of all infections detected). The population used in the model reflected the mean size of a US elementary school, including 638 students and 60 educators and staff members in 6 grades with 5 classes per grade. Variant infectiousness (representing wild-type virus, Alpha variant, and Delta variant), mitigation effectiveness (0%-100% reduction in the in-school secondary attack rate, representing increasingly intensive combinations of mitigations including masking and ventilation), and student vaccination levels were varied. The main outcomes were (1) probability of at least 1 in-school transmission per month and (2) mean increase in total infections per month among the immediate school community associated with a reduction in mitigation; multiple decision thresholds were estimated for objectives associated with each outcome. Sensitivity analyses on adult vaccination uptake, vaccination effectiveness, and testing approaches (for selected scenarios) were conducted. With student vaccination coverage of 70% or less and moderate assumptions about mitigation effectiveness (eg, masking), mitigation could only be reduced when local case incidence was 14 or fewer cases per 100 000 residents per day to keep the mean additional cases associated with reducing mitigation to 5 or fewer cases per month. To keep the probability of any in-school transmission to less than 50% per month, the local case incidence would have to be 4 or fewer cases per 100 000 residents per day. In this study, in-school mitigation measures (eg, masks) and student vaccinations were associated with substantial reductions in transmissions and infections, but the level of reduction varied across local incidence. These findings underscore the potential role for responsive plans that deploy mitigation strategies based on local COVID-19 incidence, vaccine uptake, and explicit consideration of community objectives.
Identifiants
pubmed: 35157056
pii: 2789005
doi: 10.1001/jamanetworkopen.2021.47827
pmc: PMC8845023
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2147827Subventions
Organisme : NIAID NIH HHS
ID : K01 AI141576
Pays : United States
Organisme : NIAID NIH HHS
ID : K08 AI127908
Pays : United States
Organisme : NIAID NIH HHS
ID : R37 AI058736
Pays : United States
Organisme : NIDA NIH HHS
ID : R37 DA015612
Pays : United States
Commentaires et corrections
Type : UpdateOf
Type : ErratumIn
Type : ErratumIn
Références
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
N Engl J Med. 2021 Sep 30;385(14):1330-1332
pubmed: 34469645
MMWR Morb Mortal Wkly Rep. 2021 Sep 17;70(37):1306-1311
pubmed: 34529645
Lancet Microbe. 2021 Jan;2(1):e13-e22
pubmed: 33521734
J Assoc Med Microbiol Infect Dis Can. 2020 Dec 31;5(4):223-234
pubmed: 36340059
Euro Surveill. 2020 Jul;25(29):
pubmed: 32720636
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Med Decis Making. 2013 Oct;33(7):880-90
pubmed: 23811758
Value Health. 2013 Mar-Apr;16(2):e1-5
pubmed: 23538200
Sci Adv. 2021 Jan 1;7(1):
pubmed: 33219112
JAMA Pediatr. 2021 Jan 1;175(1):73-80
pubmed: 32857112
Science. 2022 Jan 14;375(6577):eabi9069
pubmed: 34855513
Int J Infect Dis. 2020 May;94:145-147
pubmed: 32315808
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Clin Infect Dis. 2021 Nov 2;73(9):e3106-e3109
pubmed: 33075138
Ann Intern Med. 2021 Aug;174(8):1090-1100
pubmed: 34097433
Pediatrics. 2021 Oct;148(4):
pubmed: 34321339
Clin Infect Dis. 2021 Aug 2;73(3):e754-e764
pubmed: 33560412
N Engl J Med. 2021 Dec 23;385(26):2421-2430
pubmed: 34879188
Lancet Infect Dis. 2022 Feb;22(2):183-195
pubmed: 34756186
JAMA Pediatr. 2021 Nov 1;175(11):1151-1158
pubmed: 34398179
Wellcome Open Res. 2020 Apr 9;5:67
pubmed: 32685698
N Engl J Med. 2020 Sep 24;383(13):1283-1286
pubmed: 32857487
Proc Math Phys Eng Sci. 2021 Mar;477(2247):20200855
pubmed: 35153550
JAMA Intern Med. 2021 Apr 1;181(4):463-469
pubmed: 33300948
MMWR Morb Mortal Wkly Rep. 2021 Sep 10;70(36):1255-1260
pubmed: 34499627
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
N Engl J Med. 2022 Jan 6;386(1):35-46
pubmed: 34752019
JAMA. 2021 Mar 9;325(10):998-999
pubmed: 33566056
MMWR Morb Mortal Wkly Rep. 2021 Mar 26;70(12):437-441
pubmed: 33764962
Nat Med. 2021 Jan;27(1):94-105
pubmed: 33097835
Proc Natl Acad Sci U S A. 2020 May 12;117(19):10484-10491
pubmed: 32327608
Lancet. 2020 Jun 27;395(10242):1973-1987
pubmed: 32497510
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1167-1169
pubmed: 34437521
Ann Intern Med. 2020 May 05;172(9):577-582
pubmed: 32150748
MMWR Morb Mortal Wkly Rep. 2021 Jan 29;70(4):136-140
pubmed: 33507890
MMWR Morb Mortal Wkly Rep. 2021 Jul 16;70(28):1004-1007
pubmed: 34264910
Euro Surveill. 2021 Apr;26(15):
pubmed: 33860747
BMC Med. 2022 May 23;20(1):200
pubmed: 35606843
Indoor Air. 2021 Jul;31(4):1154-1163
pubmed: 33682974
PLoS Comput Biol. 2021 Jul 26;17(7):e1009149
pubmed: 34310589
N Engl J Med. 2022 Jan 13;386(2):116-127
pubmed: 34942067
J Sch Health. 2022 Jan;92(1):11-19
pubmed: 34750833